Solid Biosciences Reports Increased Loss Amid R&D Expansion

Solid Biosciences ( (SLDB) ) has released its Q1 earnings. Here is a breakdown of the information Solid Biosciences presented to its investors.

Solid Biosciences Inc., a biotechnology company, focuses on developing gene therapy candidates for rare neuromuscular and cardiac diseases. In its latest earnings report for the quarter ending March 31, 2025, the company reported a net loss of $39.3 million, compared to a $24.3 million loss in the same period last year. The increase in loss is attributed to higher research and development expenses, which rose to $30.9 million from $18.9 million. Despite the losses, Solid Biosciences successfully raised approximately $188 million through a public offering, significantly boosting its cash reserves to $210.6 million. The company remains committed to advancing its pipeline of gene therapy candidates, including SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich’s ataxia. Looking ahead, Solid Biosciences plans to continue its research and development efforts, with management expressing confidence in the company’s financial position to support operations for at least the next twelve months.